SNSS interim Phase 3 VALOR analysis due September. DYAX discontinues Phase 2 ecallantide. AEGR prices offering.

Jun 15, 2012 No Comments by

Dyax Corp. (NASDAQ: DYAX) announced that it will discontinue its Phase 2 trial of ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema following an interim analysis showing it not to be statistically effective.

Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) said that it expects interim analysis of its Phase 3 VALOR trial of vosaroxin, in patients with first relapsed or refractory acute myeloid leukemia (AML), to be completed during September 2012.

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) priced its underwritten public offering of 3.4m shares at a price to the public of $14.75 per share, for net proceeds of approximately $47.3m.

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “SNSS interim Phase 3 VALOR analysis due September. DYAX discontinues Phase 2 ecallantide. AEGR prices offering.”

Leave a Reply